Surse:

1. Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913-1924.
2. Breast Cancer Factsheet. World Health Organisation. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf Accessed September 2018.
3. Foulkes WD et al. Triple-Negative Breast Cancer. N Engl J Med. 2010;363:1938–1948.
4. Who Gets Triple Negative Breast Cancer? BreastCancer.org. Available from: http://www.breastcancer.org/types/triple-negative. Accessed July 2024.
5. Wu Y et al. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One. 2013;8(10):e78259.
6. Pal SK et al. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627–636.
7. Breast Cancer in Young Women. Healthline. Available from: http://www.healthline.com/health/breast-cancer/breast-cancer-in-young-women.
8. Li X et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2016;161(2):279-287.
9. Dent R et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 2007;13(15 pt.1):4429-4434.
10. Mittendorf EA et al. PD-L1 Expression in Triple Negative Breast Cancer. Cancer Immunol Res. 2014;2(4):361–370.